Tag: MTAI
Policy reversal on stent pricing in Gujarat: MTaI laments misleading narratives,...
While MTaI has called the portrayal of global regulatory approvals as a loophole to be misleading, AiMed has termed it a victory for the domestic manufacturers
Parliamentary panel puts CDSCO’s approach to MedTech industry under scanner, MTaI...
The committee noted that the existing licensing process is marked by delays, inconsistent timelines, and a lack of transparency
India to expand global MedTech share to 10-12% by 2030: Anupriya...
Government backs MedTech as a strategic sector, aims for $30 Billion market by 2030
MTaI to host MedTech stakeholders’ dialogue, ‘MedTekon’ in New Delhi on...
The event will focus on Investments, Reforms & Synergies in Medical Technology
Obituary: Bioscience industry pays rich tributes to Ratan Tata
His loss resonates far beyond the corridors of industry, deeply touching the lives of millions he inspired
French Healthcare meets Indian ecosystem at Indo-French Healthcare Conference
The Indo-French Healthcare Conference, which brought together healthcare professionals, medical experts and industry leaders from both France and India, aimed to create dialogues and foster collaborations
Govt issues uniform code for marketing practices for the medical device...
Department of Pharmaceuticals has asked the medical devices associations to ensure that medical devices are not promoted prior to receipt of the product approval
Budget 2024: MTaI welcomes reduction of custom duty on X ray...
The leading association of global medical technology companies has welcomed the reduction of custom duties on specific categories of medical devices and healthcare skilling
At the MTaI fraternity meeting Secretary DoP expounds the concept of...
The event was also graced by the Deputy Drugs Controller, CEOs & MDs of more than 20+ research and innovation based MedTech companies and industry stalwarts
Union Budget 2024: MTaI calls for reduction in customs duties on...
Medical Technology Association of India outlined the hurdles that still continue to restrict the sector, especially very high tariff and customs duty rates and imposition of additional health cess ad valorem